ArticleEye (London, England)2026
Endogenous endophthalmitis in a tertiary referral centre: a 14-year case series with comparative perspective.
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeEndogenous endophthalmitis (EE) is a rare but severe ocular emergency caused by haematogenous spread of infectious microorganisms. This study analyses clinical characteristics, diagnostic challenges, microbiological spectrum, and treatment outcomes of EE cases over a 14-year period, comparing findings with published data.
methodsA retrospective review was conducted on EE cases diagnosed at a tertiary care centre from 2010 to 2024. Data included demographics, clinical presentation, microbiology, diagnostics, treatment, and visual outcomes. Relevant literature was reviewed to contextualise findings and reflect on similarities and nuances in broader clinical experience.
results27 patients with EE were identified. Systemic comorbidities, including malignancies and immunosuppression, were common. Ocular symptoms were present in 77% of cases, while 22% were asymptomatic. The majority exhibited unilateral involvement. Blood cultures (BC) were performed in 77% of cases, with a positivity rate of 66%. Vitreous biopsies were conducted in nine cases, yielding a 66% positivity rate. Treatment included systemic antibiotics or antifungals, topical medications, and intravitreal therapy (81% of cases). Pars plana vitrectomy (PPV) was performed in 51% of cases, though only two underwent early PPV. Final BCVA varied widely, with 59% of eyes achieving functional recovery. 21% of cases resulted in phthisis bulbi or evisceration, and 18% of patients died during follow-up due to systemic illness.
conclusionEE presents diagnostic and therapeutic challenges, with high risk of visual impairment and systemic morbidity. Early recognition, aggressive therapy, and timely surgery may improve outcomes. Further research is needed to establish standardised diagnostic and treatment guidelines for optimal management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.